Knocking out the Adcirca CoM patent, which expires in Nov 2017, won’t provide much economic benefit to the P-IV challenger. That’s because orphan drug exclusivity in PAH, which can’t be overturned by a P-IV challenge, runs until Apr 2016.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.